Polium Technologies Closes on $750,000

Vincent Capponi Added to Board of Advisors



Apr 30, 2001, 01:00 ET from Polium Technologies

    HOFFMAN ESTATES, Ill., April 30 /PRNewswire/ -- Polium Technologies
 provides a unique solution in the production of chiral drugs for the
 pharmaceutical industry.  The company has developed proprietary technology
 that increases the efficiency and reduces the cost of bulk enantiomer drug
 manufacturing for chiral compounds such as Levibutirol.  Polium Technologies
 is the only company offering biocatalytical products of this kind to the
 market.
     Polium closed on a Phase 2 grant from the National Institute of Health for
 $750,000 on April 1.  Polium will be seeking private financing in the 3rd
 quarter of 2001 as part of the next phase of development.  Prinz and
 Associates is working with Polium to help build the management team and secure
 financing that will allow it to move from a developmental company into a
 profitable operating business.
     Joining Michael Gololobov (President and Senior Scientific Officer) and
 John Prinz (Member of the Advisory Board) is Vincent J. Capponi who was
 appointed to the Advisory Board of Polium.  Mr. Capponi has over 19 years of
 experience in the pharmaceutical, chemical and medical device industries
 serving in various senior management positions.  Mr. Capponi brings to Polium
 key skills in the area of new technology start-ups and commercialization of
 nascent technologies.  Mr. Capponi has worked for well know companies such as
 Upjohn Pharmaceuticals, Mead Paper Corp. and Baxter Healthcare.
     For more information, please call John Prinz at (847) 549-1874 or Michael
 Gololobov at (847)-310-8725.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X54764093
 
 

SOURCE Polium Technologies
    HOFFMAN ESTATES, Ill., April 30 /PRNewswire/ -- Polium Technologies
 provides a unique solution in the production of chiral drugs for the
 pharmaceutical industry.  The company has developed proprietary technology
 that increases the efficiency and reduces the cost of bulk enantiomer drug
 manufacturing for chiral compounds such as Levibutirol.  Polium Technologies
 is the only company offering biocatalytical products of this kind to the
 market.
     Polium closed on a Phase 2 grant from the National Institute of Health for
 $750,000 on April 1.  Polium will be seeking private financing in the 3rd
 quarter of 2001 as part of the next phase of development.  Prinz and
 Associates is working with Polium to help build the management team and secure
 financing that will allow it to move from a developmental company into a
 profitable operating business.
     Joining Michael Gololobov (President and Senior Scientific Officer) and
 John Prinz (Member of the Advisory Board) is Vincent J. Capponi who was
 appointed to the Advisory Board of Polium.  Mr. Capponi has over 19 years of
 experience in the pharmaceutical, chemical and medical device industries
 serving in various senior management positions.  Mr. Capponi brings to Polium
 key skills in the area of new technology start-ups and commercialization of
 nascent technologies.  Mr. Capponi has worked for well know companies such as
 Upjohn Pharmaceuticals, Mead Paper Corp. and Baxter Healthcare.
     For more information, please call John Prinz at (847) 549-1874 or Michael
 Gololobov at (847)-310-8725.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X54764093
 
 SOURCE  Polium Technologies